NCT04401475Phase 2, phase 3Terminated

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19

Study sponsor: Edesa Biotech Inc. · EDSA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-07-22Actual
Enrollment · participants278Actual
Source updated2026-10-28Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Mortality rate at Day 28 from IP administration. Description: For the current study, the primary efficacy outcome measure will be the mortality rate from IP administration. Mortality is the most clinically relevant therapeutic endpoint for this population that is on IMV. The primary endpoint will be assessed at 28-days after treatment initiation. Time frame: 28 days. After: Measure: Mortality rate at Day 28 from IP administration. (Phase 2 and 3) Description: For the current study, the primary efficacy outcome measure will be the mortality rate from IP administration. Mortality is the most clinically relevant therapeutic endpoint for this population that is on IMV. The primary endpoint will be assessed at 28-days after treatment initiation. Time frame: 28 days.

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 644 participants (planned). After: 278 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Dec 2024. After: 22 Jul 2024.

Recruitment status changed

Before: Suspended. After: Terminated.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview